Indoco Remedies

Quick check

The five things to look at first. Open one for more.

• DebtAdequate safety, with cautionRated A by ICRA.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 6.4% and profit rose 281% from a year earlier. (A year earlier it made a loss.)
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 59% of the company, about the same as in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 125.9 times its yearly earnings (P/E), pricier than 98% of the time in the last 3 years. Its usual P/E is about 22.

Indoco Remedies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)125.9 against a typical 34.6: pricier than most peers (1st = cheapest).199th of 220
• Sales growth+6.4% against a typical +15.6% from a year earlier.129th of 197
• Share price, 3 months−4.8% against a typical −0.5%.121st of 200

Exchange filings and their impact on the company.

• 27 Oct 2026Press ReleaseLow impactPositivePrice −2.9% on 28 Oct
  AnaCipher wins Brazil ANVISA approval, opening a small new regulated CRO revenue stream.

  Indoco Remedies said its clinical research arm AnaCipher has received approval from ANVISA Brazil for its clinical and bioanalytical facilities. This allows AnaCipher to conduct bioequivalence and other studies accepted by the Brazilian regulator. It opens Brazil-linked outsourcing demand for the CRO, with only a modest near-term revenue contribution relative to Indoco's size.

  Full analysisFiling
• 27 Oct 2026Outcome of Board MeetingMedium impactPositivePrice +0.5% that day
  Revenue up ~7-8% with margin steady near 9%, but profit is one-off property-sale driven as core operations still loss-making.

  Indoco Remedies reported Q2FY27 consolidated revenues of Rs 506.9 crore, up 7.4% year-on-year, with EBITDA of Rs 46.4 crore at 9.2% margin. H1 revenues were Rs 973.1 crore, up 7.8%, with EBITDA margin improving to 9% from 6.7%. Reported profit of Rs 19.5 crore in Q2 and Rs 84.9 crore in H1 was driven by a one-off exceptional gain of about Rs 37 crore in Q2 from sale of its Andheri property, as core operations before exceptionals remained in loss.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Aditi Kare Panandikar

Chief Executive Officer, Managing Director, Executive Director

Pramod Ghorpade

Chief Financial Officer

Ramanathan Hariharan

Compliance Officer, Company Secretary, Head - Legal

Sundeep V. Bambolkar

Joint Managing Director, Executive Director